Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators. Wykrzykowska JJ, et al. Among authors: arkenbout ek. N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29. N Engl J Med. 2017. PMID: 28402237 Free article. Clinical Trial.
Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation.
Bonta PI, Pols TW, van Tiel CM, Vos M, Arkenbout EK, Rohlena J, Koch KT, de Maat MP, Tanck MW, de Winter RJ, Pannekoek H, Biessen EA, Bot I, de Vries CJ. Bonta PI, et al. Among authors: arkenbout ek. Circulation. 2010 May 11;121(18):2023-32. doi: 10.1161/CIRCULATIONAHA.109.885673. Epub 2010 Apr 26. Circulation. 2010. PMID: 20421523
A systematic review and meta-analysis on primary percutaneous coronary intervention of an unprotected left main coronary artery culprit lesion in the setting of acute myocardial infarction.
Vis MM, Beijk MA, Grundeken MJ, Baan J Jr, Koch KT, Wykrzykowska JJ, Arkenbout EK, Tijssen JG, de Winter RJ, Piek JJ, Henriques JP. Vis MM, et al. Among authors: arkenbout ek. JACC Cardiovasc Interv. 2013 Apr;6(4):317-24. doi: 10.1016/j.jcin.2012.10.020. JACC Cardiovasc Interv. 2013. PMID: 23597607 Free article. Review.
Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
Woudstra P, Grundeken MJ, Kraak RP, Hassell ME, Arkenbout EK, Baan J Jr, Vis MM, Koch KT, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP, Wykrzykowska JJ. Woudstra P, et al. Among authors: arkenbout ek. Am Heart J. 2014 Feb;167(2):133-40. doi: 10.1016/j.ahj.2013.09.017. Epub 2013 Oct 17. Am Heart J. 2014. PMID: 24439973 Free article. Clinical Trial.
Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, Baan J Jr, Vis MM, Arkenbout EK, Tijssen JG, de Winter RJ, Wykrzykowska JJ. Kraak RP, et al. Among authors: arkenbout ek. EuroIntervention. 2015 Feb;10(10):1160-8. doi: 10.4244/EIJY14M08_08. EuroIntervention. 2015. PMID: 25136885 Free article.
Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling.
Medzikovic L, Schumacher CA, Verkerk AO, van Deel ED, Wolswinkel R, van der Made I, Bleeker N, Cakici D, van den Hoogenhof MM, Meggouh F, Creemers EE, Remme CA, Baartscheer A, de Winter RJ, de Vries CJ, Arkenbout EK, de Waard V. Medzikovic L, et al. Among authors: arkenbout ek. Sci Rep. 2015 Oct 21;5:15404. doi: 10.1038/srep15404. Sci Rep. 2015. PMID: 26486271 Free PMC article.
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
de Winter RJ, Katagiri Y, Asano T, Milewski KP, Lurz P, Buszman P, Jessurun GAJ, Koch KT, Troquay RPT, Hamer BJB, Ophuis TO, Wöhrle J, Wyderka R, Cayla G, Hofma SH, Levesque S, Żurakowski A, Fischer D, Kośmider M, Goube P, Arkenbout EK, Noutsias M, Ferrari MW, Onuma Y, Wijns W, Serruys PW. de Winter RJ, et al. Among authors: arkenbout ek. Lancet. 2018 Feb 3;391(10119):431-440. doi: 10.1016/S0140-6736(17)33103-3. Epub 2017 Dec 5. Lancet. 2018. PMID: 29203070 Clinical Trial.
Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.
Kraak RP, Kajita AH, Garcia-Garcia HM, Henriques JPS, Piek JJ, Arkenbout EK, van der Schaaf RJ, Tijssen JGP, de Winter RJ, Wykrzykowska JJ. Kraak RP, et al. Among authors: arkenbout ek. Catheter Cardiovasc Interv. 2018 Aug 1;92(2):E106-E114. doi: 10.1002/ccd.27475. Epub 2018 Jan 14. Catheter Cardiovasc Interv. 2018. PMID: 29332307
36 results